Mona Shafey

495 total citations
36 papers, 245 citations indexed

About

Mona Shafey is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Mona Shafey has authored 36 papers receiving a total of 245 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 17 papers in Oncology and 12 papers in Genetics. Recurrent topics in Mona Shafey's work include Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Mona Shafey is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Mona Shafey collaborates with scholars based in Canada, United States and Japan. Mona Shafey's co-authors include Douglas A. Stewart, Peter Duggan, Jan Storek, Andrew Daly, Carolyn Owen, Robert Puckrin, Mary Lynn Savoie, Nizar J. Bahlis, Michelle Geddes and James A. Russell and has published in prestigious journals such as Blood, British Journal of Haematology and Thrombosis and Haemostasis.

In The Last Decade

Mona Shafey

28 papers receiving 243 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mona Shafey Canada	9	107	96	69	45	43	36	245
Tsuneaki Hirakawa Japan	6	98 0.9×	83 0.9×	71 1.0×	30 0.7×	56 1.3×	20	248
Antonella Romanelli Italy	7	110 1.0×	127 1.3×	132 1.9×	41 0.9×	45 1.0×	9	333
Kevin Imrie Canada	11	86 0.8×	140 1.5×	153 2.2×	62 1.4×	24 0.6×	16	332
Michelle Chiu United States	7	195 1.8×	80 0.8×	38 0.6×	30 0.7×	72 1.7×	12	309
Blanca Boluda Spain	9	104 1.0×	103 1.1×	29 0.4×	19 0.4×	24 0.6×	32	250
Amir Steinberg United States	8	98 0.9×	89 0.9×	27 0.4×	23 0.5×	26 0.6×	73	221
C Sarkodee-Adoo United States	9	199 1.9×	128 1.3×	89 1.3×	58 1.3×	36 0.8×	18	354
Patricia Franchi France	8	27 0.3×	85 0.9×	120 1.7×	36 0.8×	20 0.5×	13	193
Elva Jiménez‐Hernández Mexico	10	79 0.7×	95 1.0×	27 0.4×	27 0.6×	105 2.4×	33	312
Mohsen Alzahrani Saudi Arabia	8	76 0.7×	37 0.4×	39 0.6×	74 1.6×	15 0.3×	58	214

Countries citing papers authored by Mona Shafey

Since Specialization

Citations

This map shows the geographic impact of Mona Shafey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mona Shafey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mona Shafey more than expected).

Fields of papers citing papers by Mona Shafey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mona Shafey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mona Shafey. The network helps show where Mona Shafey may publish in the future.

Co-authorship network of co-authors of Mona Shafey

This figure shows the co-authorship network connecting the top 25 collaborators of Mona Shafey. A scholar is included among the top collaborators of Mona Shafey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mona Shafey. Mona Shafey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shafey, Mona, et al.. (2025). Improving Patient Access through Value-Based CAR T Delivery: Examples Using a Micro-costing Tool. Transplantation and Cellular Therapy. 31(9). 655–665.

Stewart, Douglas A., John Kuruvilla, David M. Lee, et al.. (2024). Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP. British Journal of Haematology. 205(3). 881–890.

Mangoff, Kathryn, Rebecca F. McClure, Mona Shafey, et al.. (2024). Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses. Blood. 144(Supplement 1). 6291–6291.

Puckrin, Robert, Neil Chua, Carolyn Owen, et al.. (2023). Consolidative Autotransplantation Achieves High Cure Rates in Adverse-Risk Large B Cell Lymphoma. Transplantation and Cellular Therapy. 29(12). 763.e1–763.e5.

Berinstein, Neil L., Kees-Peter de Roos, Rebecca F. McClure, et al.. (2023). Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM). Hematological Oncology. 41(S2). 396–397. 1 indexed citations

Puckrin, Robert, Mona Shafey, & Jan Storek. (2023). The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review. Frontiers in Oncology. 12. 1105779–1105779. 5 indexed citations

Abedin, Tasnima, S. Ali Naqvi, Hua Shen, et al.. (2022). Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation. Blood Advances. 6(3). 767–773. 7 indexed citations

Puckrin, Robert, et al.. (2022). Favorable Outcomes with R-CHOP Induction and Consolidative Autologous Stem Cell Transplantation for Double-Hit Lymphoma. Transplantation and Cellular Therapy. 28(11). 762.e1–762.e4. 1 indexed citations

Puckrin, Robert, Douglas A. Stewart, & Mona Shafey. (2022). Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis. Transplantation and Cellular Therapy. 28(4). 218.e1–218.e4. 6 indexed citations

10.

Williamson, Tyler, Na Li, Faisal M. Khan, et al.. (2022). Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder. Transplantation and Cellular Therapy. 29(1). 43.e1–43.e8. 9 indexed citations

11.

Williamson, Tyler, Kareem Jamani, Ahsan Chaudhry, et al.. (2021). Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(1). 53.e1–53.e10. 15 indexed citations

12.

Dolan, Sean, Anna Christofides, Sarah Doucette, & Mona Shafey. (2020). Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia. Current Oncology. 27(4). 420–432. 5 indexed citations

13.

Chua, Neil, et al.. (2019). Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients. Biology of Blood and Marrow Transplantation. 25(8). 1505–1510. 8 indexed citations

14.

Davidson, Marta, Douglas A. Stewart, Peter Duggan, Andrew Daly, & Mona Shafey. (2017). Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis. Blood. 130. 4534–4534. 1 indexed citations

15.

Russell, James A., Tyler Williamson, M. Ahsan Chaudhry, et al.. (2013). Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation. Biology of Blood and Marrow Transplantation. 19(9). 1381–1386. 27 indexed citations

16.

Duan, Qiuli, Jan‐Willem Henning, Peter Duggan, et al.. (2013). High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma. Leukemia & lymphoma. 54(12). 2620–2626. 5 indexed citations

17.

Daly, Andrew, Mary Lynn Savoie, Michelle Geddes, et al.. (2012). Fludarabine, Busulfan, Antithymocyte Globulin, and Total Body Irradiation for Pretransplantation Conditioning in Acute Lymphoblastic Leukemia: Excellent Outcomes in All but Older Patients with Comorbidities. Biology of Blood and Marrow Transplantation. 18(12). 1921–1926. 17 indexed citations

18.

Ng, Ella S.M., M. Ahsan Chaudhry, Judy Wu, et al.. (2011). Development and Validation of a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed Infusion Rate Dosing. Biology of Blood and Marrow Transplantation. 18(2). 295–301. 31 indexed citations

19.

Shafey, Mona, Qiuli Duan, James A. Russell, et al.. (2011). Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. Leukemia & lymphoma. 53(4). 596–602. 7 indexed citations

20.

Shafey, Mona, et al.. (2010). Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment. Bone Marrow Transplantation. 46(7). 962–969. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact